Pharmaceutical company AstraZeneca PLC is reorganizing its global research and development operations and eliminating roughly 1,800 R&D jobs as part of a previously announced cost-cutting plan, according to the Associated Press. About 550 jobs will be eliminated at AstraZeneca''s U.S. headquarters in Delaware as it moves primary research and development elsewhere, the London-based company said. AstraZeneca also said it will close research sites in the United Kingdom and Sweden, and that about 3,500 R&D jobs will be affected as part of a plan announced in January to cut 8,000 jobs, or 12 percent of its workforce, by 2014. The termination of psychiatric laboratory research in Delaware represents about one-third of the company''s R&D work force in the state, where future R&D efforts will focus on shepherding drugs through clinical trials and regulatory approval. AstraZeneca said its facilities in Boston will see some growth as employees transfer from other sites.